Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $47,120.94 in Stock

Twist Bioscience Co. (NASDAQ:TWSTGet Free Report) SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $51.33, for a total transaction of $47,120.94. Following the completion of the transaction, the senior vice president now directly owns 90,593 shares of the company’s stock, valued at $4,650,138.69. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Paula Green also recently made the following trade(s):

  • On Friday, May 3rd, Paula Green sold 910 shares of Twist Bioscience stock. The stock was sold at an average price of $37.13, for a total transaction of $33,788.30.
  • On Tuesday, April 2nd, Paula Green sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $32.74, for a total value of $7,497.46.
  • On Wednesday, March 20th, Paula Green sold 200 shares of Twist Bioscience stock. The stock was sold at an average price of $33.52, for a total value of $6,704.00.

Twist Bioscience Trading Up 1.6 %

Twist Bioscience stock opened at $52.44 on Thursday. The company’s 50-day moving average price is $39.00 and its two-hundred day moving average price is $36.23. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of -15.61 and a beta of 1.78. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $55.26.

Twist Bioscience (NASDAQ:TWSTGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. The business had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The business’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same quarter last year, the business earned ($1.06) earnings per share. Research analysts expect that Twist Bioscience Co. will post -3.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TWST has been the topic of several analyst reports. Evercore ISI increased their target price on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Guggenheim began coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price objective on the stock. Robert W. Baird boosted their target price on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Barclays raised their price target on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Finally, Scotiabank boosted their price objective on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, May 6th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $44.00.

Check Out Our Latest Analysis on Twist Bioscience

Institutional Trading of Twist Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of TWST. American International Group Inc. boosted its stake in Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after buying an additional 213 shares in the last quarter. D.A. Davidson & CO. boosted its position in shares of Twist Bioscience by 3.4% during the 4th quarter. D.A. Davidson & CO. now owns 16,774 shares of the company’s stock valued at $618,000 after purchasing an additional 554 shares in the last quarter. EdgeRock Capital LLC acquired a new position in shares of Twist Bioscience in the 4th quarter worth approximately $30,000. Swiss National Bank raised its holdings in shares of Twist Bioscience by 0.8% in the 1st quarter. Swiss National Bank now owns 114,000 shares of the company’s stock worth $3,911,000 after purchasing an additional 900 shares in the last quarter. Finally, ProShare Advisors LLC lifted its stake in Twist Bioscience by 10.2% during the first quarter. ProShare Advisors LLC now owns 14,444 shares of the company’s stock valued at $496,000 after purchasing an additional 1,336 shares during the last quarter.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Articles

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.